

Genome-wide association study identifies Alzheimer's risk variant in MS4A6A influencing cerebrospinal fluid sTREM2 levels



Xiao-He Hou^{a,1}, Yan-Lin Bi^{b,1}, Meng-Shan Tan^a, Wei Xu^a, Jie-Qiong Li^a,
Xue-Ning Shen^a, Kai-Xin Dou^a, Chen-Chen Tan^a, Lan Tan^a, Alzheimer's Disease
Neuroimaging Initiative², Jin-Tai Yu^{c,*}

^a Department of Neurology, Qingdao Municipal Hospital, Qingdao University, China

^b Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao University, China

^c Department of Neurology and Institute of Neurology, WHO Collaborating Center for Research and Training in Neurosciences, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

ARTICLE INFO

Article history:

Received 13 November 2018

Received in revised form 25 March 2019

Accepted 13 May 2019

Available online 21 May 2019

Keywords:

TREM2

MS4A6A

Alzheimer's disease

Genome-wide association study

ABSTRACT

The triggering receptor expressed on myeloid cells 2 (*TREM2*) gene has been reported to increase the risk of Alzheimer's disease (AD). The soluble *TREM2* protein (sTREM2) in cerebrospinal fluid (CSF) was also associated with AD. However, the role of sTREM2 in AD and its genetic modifiers remain unclear. We carried out a genome-wide association study for CSF sTREM2 levels using participants from the Alzheimer's Disease Neuroimaging Initiative and validated the significant association in an independent cohort from Chinese Alzheimer's Biomarker and Lifestyle study. rs7232 in membrane spanning 4-domains A6A (*MS4A6A*) gene was associated with CSF sTREM2 levels at genome-wide significance ($p = 1.42 \times 10^{-15}$). The locus influences CSF sTREM2 levels especially in nondemented individuals. And the association was replicable in the validation cohort from Chinese Alzheimer's Biomarker and Lifestyle study ($p = 0.0106$). Besides, the expressions of *MS4A6A* and *TREM2* were correlated in brain regions ($p < 2 \times 10^{-16}$). The findings of our study suggest that the AD risk variant in the *MS4A6A* gene participates in the regulation of sTREM2.

© 2019 Elsevier Inc. All rights reserved.

1. Introduction

Heterozygous mutations in the triggering receptor expressed on myeloid cells 2 (*TREM2*) gene have been demonstrated to be associated with increased risk of Alzheimer's disease (AD). The functional p.R47H variant increases susceptibility to late-onset AD in Caucasians with an odds ratio similar to that of apolipoprotein E (*APOE*) ϵ 4 allele (Guerreiro et al., 2013; Jonsson et al., 2013; Neumann et al., 2013). Besides, p.H157Y in *TREM2* exon 3 was also associated with increased risk of AD in Han Chinese population (Jiang et al.,

2016a). It has been suggested that *TREM2* protein also plays a role in AD-related pathology, including amyloid- β (A β) deposition and tau hyperphosphorylation (Gao et al., 2017). *TREM2* protein is an innate immune receptor primarily expressed on the surface of microglia. *TREM2* has functions of suppressing inflammatory responses and regulating phagocytic pathways (Bajramovic et al., 2011; Hsieh et al., 2009). Loss of function of *TREM2* could impair microglial clearance of A β (Frank et al., 2008).

A soluble form of *TREM2* (sTREM2) which is released by ecto-domain cleavage of *TREM2* can be measured in the cerebrospinal fluid (CSF) (Piccio et al., 2008). It has been found that *TREM2* is shed predominantly at the H157-S158 peptide bond where the risk variant p.H157Y has been discovered in Han Chinese population (Schleppack et al., 2017; Thornton et al., 2017). sTREM2 was considered a potential biomarker implicated in AD (Heslegrave et al., 2016; Piccio et al., 2016; Suarez-Calvet et al., 2016b). The levels of CSF sTREM2 are correlated with the levels of CSF AD-related biomarkers t-tau and p-tau (Alosco et al., 2018; Heslegrave et al., 2016). It is also associated with gray matter volume in the early stage of AD (Gispert et al., 2016). In addition, sTREM2 could induce inflammatory responses and increase microglial survival (Zhong et al., 2017). And it is

* Corresponding author at: Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, 12th Wulumuqi Zhong Road, Shanghai 200040, China. Tel.: +86 21 52888160; fax: +86 21 62483421.

E-mail address: jintai_yu@fudan.edu.cn (J.-T. Yu).

¹ X.H. Hou and Y.L. Bi contributed equally to this work.

² Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.

reported that microglia activation that precedes the onset of AD could be reflected by higher levels of CSF sTREM2 (Hamelin et al., 2016; Suarez-Calvet et al., 2016b). These findings suggested that sTREM2 may be involved in AD pathology (Heslegrave et al., 2016; Piccio et al., 2016). However, the potential role of sTREM2 in AD and its genetic modifiers remain unclear.

In our study, we performed a genome-wide association study (GWAS) and a subgroup analysis for CSF sTREM2 to discover potential genetic factors involved in sTREM2, which demonstrated that AD risk variants in membrane spanning 4-domains A6A (MS4A6A) gene could influence CSF sTREM2 levels, especially in nondemented elders.

2. Materials and methods

2.1. Participants

In this study, 449 and 179 non-Hispanic white individuals whose data met all quality control (QC) criteria were included from the Alzheimer's Disease Neuroimaging Initiative (ADNI) 1/GO/2 cohorts and ADNI-1 cohort, respectively. The demographic information for participants and description of their CSF sTREM2 levels are shown in Table 1.

The full cohort with both sTREM2 and genotype data included 508 participants from ADNI-1/GO/2 cohorts and 281 participants from ADNI-1 cohort. There are some overlaps between the participants of ADNI-1/GO/2 cohorts and ADNI-1 cohort. Eight-four individuals in both ADNI-1/GO/2 cohorts and ADNI-1 cohort were removed from ADNI-1 cohort in our study. To reduce potential bias due to population stratification, all the subjects were restricted to non-Hispanic Caucasians. This step removed 48 subjects from ADNI-1/GO/2 cohorts and 18 subjects from ADNI-1 cohort. Population substructure and cryptic relatedness were tested with multidimensional scaling components and genomic identity by descent. This step removed 2 participants from ADNI-1/GO/2 cohorts who were cryptically related and clustering separately from the other samples (024_S_2239 and 024_S_4084, $\pi = 0.423$).

2.2. ADNI data set

Data used in the preparation for this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-

private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging, positron emission tomography, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early AD. For up-to-date information, see www.adni-info.org.

2.3. IGAP data set

International Genomics of Alzheimer's Project (IGAP) is a large two-stage study based on GWASs in individuals of European ancestry. In stage 1, IGAP used genotyped and imputed data on 7,055,881 single-nucleotide polymorphisms (SNPs) to meta-analyze four previously published GWAS data sets consisting of 17,008 AD cases and 37,154 controls (The European Alzheimer's disease Initiative; the Alzheimer Disease Genetics Consortium; the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium; and the Genetic and Environmental Risk in AD consortium). In stage 2, 11,632 SNPs were genotyped and tested for association in an independent set of 8572 AD cases and 11,312 controls. Finally, a meta-analysis was performed combining results from stages 1 and 2.

2.4. Braineac data sets

The Braineac is a web-based tool to access the expression quantitative trait loci (eQTLs) data sets from the UK Brain Expression Consortium (Ramasamy et al., 2014). The data sets are available online for the exploration of the regulatory significance of genetic variants in the human brain (<http://www.braineac.org/>). The Braineac includes 10 eQTLs data sets covering 10 human brain regions including cerebellar cortex, frontal cortex, hippocampus, medulla (specifically inferior olivary nucleus), occipital cortex, putamen, substantia nigra, temporal cortex, thalamus, and intralobular white matter. More detailed information is described in the original study (Ramasamy et al., 2014).

2.5. CSF sTREM2 measurements and QC

CSF sTREM2 measurements were carried out with the enzyme-linked immunosorbent assay (ELISA) protocol previously established by the Haass' group with minor changes. The assay is based

Table 1
Demographic information

Baseline diagnosis	AD	MCI	HC	Total	<i>p</i>
ADNI-1/GO/2 cohorts					
N	27	270	152	449	—
Age, mean $\pm$ SD y	75.2 $\pm$ 10.5	71.7 $\pm$ 7.3	74.7 $\pm$ 5.6	72.9 $\pm$ 7.1	0.09
M/F, n	17/10	163/107	81/71	261/188	0.32
APOE ϵ 4 carrier, %	66.7	45.6	21.7	38.8	<0.001
CSF sTREM2, mean $\pm$ SD pg/mL	4865.7 $\pm$ 2718.5	4009.7 $\pm$ 1894.9	4178.6 $\pm$ 1947.8	4118.4 $\pm$ 1989.8	0.09
ADNI-1 cohort					
N	69	80	30	179	—
Age, mean $\pm$ SD y	74.3 $\pm$ 8.3	75.2 $\pm$ 7.5	76.2 $\pm$ 6.1	75.0 $\pm$ 7.6	0.25
M/F, n	36/36	47/33	18/12	101/78	0.48
APOE ϵ 4 carrier, %	68.1	55.0	30.0	55.3	0.002
CSF sTREM2, mean $\pm$ SD pg/mL	4111.1 $\pm$ 1602.7	4023.8 $\pm$ 1790.3	4621.7 $\pm$ 1903.3	4156.7 $\pm$ 1743.3	0.30
CABLE cohort					
N	—	130	247	377	—
Age, mean $\pm$ SD y	—	64.3 $\pm$ 9.8	60.9 $\pm$ 10.8	62.1 $\pm$ 10.5	0.01
M/F, n	—	70/60	140/107	210/167	0.68
CSF sTREM2, mean $\pm$ SD pg/mL	—	16,303.6 $\pm$ 6824.1	15,600.7 $\pm$ 6846.4	15,712.0 $\pm$ 6843.2	0.23

Key: AD, Alzheimer's disease; ADNI, Alzheimer's Disease Neuroimaging Initiative; APOE, apolipoprotein E; CSF, cerebrospinal fluid; CABLE, Chinese Alzheimer's Biomarker and Lifestyle; HC, healthy control; MCI mild cognitive impairment; SD; standard deviation; sTREM2, soluble TREM2 protein.

on the MSD platform as previously described (Suarez-Calvet et al., 2016a, b). The assay consists of a biotinylated polyclonal goat anti-human TREM2 antibody as a capture antibody, a monoclonal mouse anti-human TREM2 antibody as a detection antibody, and a SULFO-TAG–labeled anti-mouse secondary antibody. Recombinant human TREM2 protein was used as a standard (62.5–8000 pg/mL). All CSF samples were distributed randomly across plates and measured in duplicate. And all the antibodies and plates were from a single lot to exclude variability between batches. The experiment was performed by operators experienced in running the assays and blinded to the clinical information. The mean intraplate coefficient of variation was 3.1%. All duplicate measures had a coefficient of variation < 15%.

Mean and standard deviation (SD) of CSF sTREM2 measures were calculated to reduce the potential influence of extreme outliers on statistical results. Participants who had a value which was 4-fold SD greater or smaller than the mean value (4118.35 pg/mL for ADNI-1/GO/2 cohorts and 4157.67 for ADNI-1 cohort) were removed from the analysis. This step removed 3 additional participants from ADNI-1/GO/2 cohorts. The CSF sTREM2 levels were measured by two research groups. There was a strong correlation between the corrected values of sTREM2 in the two groups. And individuals with CSF sTREM2 levels that fell outside the prediction intervals (based on 98% tolerance) were removed. This step removed 6 participants from ADNI-1/GO/2 cohorts.

2.6. Genotyping and QC

The ADNI-1/GO/2 samples were genotyped with the Omni 2.5 M BeadChip (Illumina, Inc, San Diego, CA). The ADNI-1 samples were genotyped with the Human 610-Quad BeadChip (Illumina, Inc, San Diego, CA). Genome-wide complex trait analysis was used to calculate principal component factors for each sample (Price et al., 2006). The 1000 Genome Data and BEAGLE software (version 5.0) were used for imputating the individual genotypes of ADNI-1/GO/2 cohorts (Browning and Browning, 2007). Following the standard procedure, imputation was conducted using the Beagle software (version 5.0) with the HapMap GRCh37 as reference. SNPs with a Beagle $R^2 < 0.8$, a call rate <95%, a minor allele frequency (MAF) <0.2, and Hardy-Weinberg equilibrium test $p < 0.001$ were removed. The individual genotypes of ADNI-1 cohort were not imputed in our study because they were mapped based on GRCh36. The genetic association analyses were performed using the PLINK software (version 1.07) with the following criteria: call rate for SNPs > 95%, call rate for individuals > 90%, MAF > 0.20, and Hardy-Weinberg equilibrium test $p > 0.001$. APOE alleles which were defined by rs7421 and rs429358 were genotyped separately by an APOE genotyping kit (Kim et al., 2011). Finally, a total of 3,263,912 imputed and genotyped SNPs passed filters and QC were included for analyses in ADNI-1/GO/2 cohort. And 319,112 SNPs passed filters and QC were included for analyses in ADNI-1 cohort.

2.7. Replication in CABLE study

Three hundred and seventy-seven elders who were northern Han Chinese in origin were derived from Chinese Alzheimer's Biomarker and Lifestyle (CABLE) study as an independent replication cohort.

CABLE is a large-scale cohort study mainly focusing on Alzheimer's risk factors and biomarkers in Chinese Han population. CABLE aimed to determine the genetic and environmental modifiers of AD biomarkers and their utility in AD early diagnosis. Identification of lifestyle factors that may influence the risk of AD in Chinese Han population was also one of the aims of CABLE. The samples in CABLE study were recruited at Qingdao Municipal

Hospital, consisting of cognitively normal elders and individuals with MCI or AD.

The diagnosis of AD was made by experienced clinicians according to the criteria of National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association. The general cognitive function was assessed by an adapted Chinese version of Mini-Mental State Examination and Montreal Cognitive Assessment.

All participants were Han Chinese in origin and aged between 50 to 90 years. The exclusion criteria were (1) central nervous system infection, head trauma, epilepsy, multiple sclerosis, or other major neurological disorders; (2) major psychological disorders (e.g., depression); (3) severe systemic diseases (e.g., malignant tumors) that may affect CSF or blood levels of AD biomarkers including A β and tau; (4) family history of genetic disease. All participants underwent clinical and neuropsychological assessments, biochemical testing, as well as blood and CSF sample collection. Demographic information, AD risk factor profile, and medical history were also collected by a comprehensive questionnaire and an electronic medical record system.

CSF sTREM2 concentrations were determined with the ab224881 Human TREM2 SimpleStep ELISA kit from Abcam at the Qingdao University. CSF samples were diluted 4-fold. SNPs for the validation stage were chosen on the basis of the genome-wide study in the initial analysis. Genotyping of these SNPs was performed using SNaPshot Multiplex System (Applied Systems) following the manufacture's protocol. Participants who had a value which was 4-fold SD greater or smaller than the mean value (15,677.15 pg/mL) were removed from the analysis. In total, CSF sTREM2 levels and genotyping of rs7232 were obtained from 377 participants. Data analysis was performed with linear regression implemented in R, accounting for age, sex, and diagnosis as covariates.

2.8. Standard protocol approvals, registrations, and patient consents

The ADNI study was approved by the institutional review board at each of the participating centers, and all participants provided written informed consent.

The CABLE study was conducted in accordance with the Helsinki declaration, and the protocol for this study was approved by the Institutional Ethics Committees of Qingdao Municipal Hospital. Written informed consent was obtained from all study participants directly or from their caregivers.

2.9. Statistical analyses

Associations between CSF sTREM2 levels and the genetic variants were determined using PLINK (version 1.07) with the additive genetic model, with each SNP represented as a count of the number of minor alleles. Age, sex, diagnosis, and the two principal component factors from population stratification analysis were included as covariates. To adjust for multiple testing, the thresholds of $p < 1 \times 10^{-5}$ and $p < 5 \times 10^{-8}$ were used for suggestive and genome-wide significant associations, respectively (Risch and Merikangas, 1996). The effects of genotypes on CSF sTREM2 were examined with a multiple linear regression implemented in R, accounting for age and sex as covariates. The potential associations between SNPs and gene expression were examined by a linear regression analysis under an additive genetic model using data from Brainiac data set. Regional associations were visualized with the LocusZoom web tool (<http://locuszoom.org/>).

3. Results

3.1. Characteristics of included subjects

A total of 449 individuals from ADNI-1/GO/2 cohorts and 179 individuals from ADNI-1 cohort were included in our GWAS (Table 1). In summary, 27 AD (75.2 ± 10.5 years), 270 MCI (71.7 ± 7.3 years), and 179 healthy control (HC) (74.7 ± 5.6 years) subjects from ADNI-1/GO/2 cohort and 69 AD (74.3 ± 8.3 years), 80 MCI (75.2 ± 7.5 years), and 30 HC (76.2 ± 6.1 years) subjects from ADNI-1 cohort were included in this study. The AD group had the highest frequency of $\epsilon 4$ allele within the *APOE* gene in both ADNI-1/GO/2 (66.7%) cohorts and ADNI-1 cohort (68.1%). CSF sTREM2 levels are positively correlated with age in all participants ($p = 9.28 \times 10^{-9}$). However, there is no significant difference among the CSF sTREM2 levels of three diagnostic groups ($p = 0.09$ in ADNI-1/GO/2 cohort, $p = 0.30$ in ADNI = 1 cohort, after ANOVA and Tukey's multiple comparisons test).

3.2. rs7232 in MS4A6A is associated with CSF sTREM2 levels

After adjusting for age, gender, diagnosis, and the two principal component factors, rs7232 in *MS4A6A* was identified as the top SNP that was significantly associated with CSF sTREM2 levels ($p = 1.42 \times 10^{-15}$) in ADNI-1/GO/2 cohorts (Fig. 1A). The minor allele (A) of rs7232 was associated with higher CSF sTREM2 levels in a dose-

dependent manner. The nearby SNPs and their linkage disequilibrium (LD) patterns with rs7232 are shown in Fig. 1B. Several SNPs in LD with rs7232 showed association with CSF sTREM2 levels with the $p < 0.01$. However, no SNPs were still strongly associated with CSF sTREM2 levels after controlling for the rs7232 genotype (Fig. 1C), indicating that the nearby SNPs were driven by rs7232.

In the ADNI-1 cohort, rs17602572 in *MS4A6A*, which was in LD with rs7232 ($r^2 = 0.75$), was identified as the only SNP associated with CSF sTREM2 levels at genome-wide significance ($p = 3.30 \times 10^{-8}$; Supplementary Fig. S1A). Regional association analysis showed that no SNPs were still associated with CSF sTREM2 levels after controlling for rs17602572 (Supplementary Fig. S1B and C). rs7232 was not included in the genotype data of ADNI-1 cohort because of the different gene chips used for genotyping. However, rs17602572 was included in the genotype data of ADNI-1/GO/2 cohorts after imputation. rs17602572 was associated with CSF sTREM2 levels with p value of 1.31×10^{-12} in ADNI-1/GO/2 cohorts (Fig. 1B). And the association between rs17602572 and CSF sTREM2 levels was not significant ($p = 0.8281$) after controlling for rs7232 genotype (Fig. 1C), suggesting that the association was also driven by rs7232.

SNPs of the TREM gene cluster were also tested for association. However, no SNPs of the TREM gene cluster were strongly associated with CSF sTREM2 levels at genome-wide significance level or regional Bonferroni-adjusted significance level. *APOE* $\epsilon 4$ was not associated with CSF sTREM2 levels either ($p = 0.342$).




Fig. 1. Manhattan and regional plots for associations with CSF sTREM2 in ADNI-1/GO/2 cohorts. (A) Manhattan plots for associations with CSF sTREM2 levels in ADNI-1/GO/2 cohorts. (B) Regional association results for the *MS4A6A* region of chromosome 11. (C) Association results for chromosome 11: 57831716–61079651 controlling for rs7232. The association between rs17602572 and CSF sTREM2 levels was not significant ($p = 0.8281$) after controlling for rs7232 genotype. Abbreviations: ADNI, Alzheimer's Disease Neuroimaging Initiative; CSF, cerebrospinal fluid; sTREM2, soluble TREM2 protein; *MS4A6A*, membrane spanning 4-domains A6A.

3.3. Subgroup analyses in different diagnostic groups

Subgroup analyses were conducted to find out the association between the SNPs and CSF sTREM2 levels in different diagnostic groups. As shown in Fig. 2, the minor allele (A) of rs7232 was associated with higher CSF sTREM2 levels in a dose-dependent fashion in HCs and MCI individuals ($p = 4.32 \times 10^{-10}$ for HC, $p = 2.55 \times 10^{-7}$ for MCI). However, in the AD group, results did not show significant differences in CSF sTREM2 among three genotypes in both multiple linear regression analysis ($p = 0.109$) and ANOVA ($p = 0.172$). In nondemented individuals (HC + MCI), rs7232 is still the most significant SNP associated with CSF sTREM2 levels ($p = 5.49 \times 10^{-15}$). The same pattern was also found in ADNI-1 cohort (Supplementary Fig. S2). The association between rs17602572 and CSF sTREM2 levels was much more significant in the HC and MCI groups ($p = 4.33 \times 10^{-5}$ for HC; $p = 4.80 \times 10^{-5}$ for MCI) than that in the AD group ($p = 0.030$). And rs17602572 was still the top SNP associated with CSF sTREM2 levels in nondemented individuals from ADNI-1 cohort (1.59×10^{-7}).

3.4. Replication in an independent CABLE study

As the association between rs7232 and CSF sTREM2 was significant especially in nondemented elders, we measured CSF sTREM2 levels and genotyped rs7232 in an independent Chinese Han cohort of 377 nondemented individuals from CABLE study to validate our findings. Among them, there are 247 cognitive normal individuals and 130 individuals who were diagnosed with MCI (Table 1). In summary, the age of participants ranged from 40 to 88 years (mean 61.8 years; SD, 10.4 years). There are 167 male and 133 female participants included in the cohort. The mean CSF sTREM2 concentration was 14,602.4 pg/mL with an SD of 6808.1 pg/mL. The minor allele (A) of rs7232 was also significantly associated with higher CSF sTREM2 levels ($p = 0.0106$) after adjustment for age, sex, and diagnosis (Fig. 3).

We also performed a meta-analysis including ADNI and CABLE samples. There was no significant heterogeneity in the meta-analysis of ADNI and CABLE study ($I^2 = 0\%$). The meta-analysis showed that rs7232 was associated with CSF sTREM2 levels ($p_{\text{meta}} = 1.59 \times 10^{-11}$, Fig. 4).

3.5. Associations between the associated SNPs in MS4A6A and risks of AD

The IGAP research included 2 stages, a discovery step and a replication step. Two data sets are available from IGAP including the

results from stage 1 and the results from stage 2 with the combined stage 1/stage 2 p -values (Lambert et al., 2013). The two SNPs (rs7232 and rs17602572) associated with CSF sTREM2 levels were available in IGAP data set. And both rs7232 and rs17602572 were identified as protective loci for AD in combined data set of IGAP stages 1 and 2 (rs7232: OR, 0.90; 95% CI, 0.87–0.92; $p = 2.621 \times 10^{-14}$; rs17602572: OR, 0.90; 95% CI 0.88–0.93; $p = 1.418 \times 10^{-14}$).

3.6. Expression quantitative trait loci analysis

Large-scale blood eQTLs data sets were used to determine whether rs7232 was reported eQTLs (Westra et al., 2013). The associations between rs7232 and gene expression in human brain tissues were analyzed by a linear regression analysis with the Brainiac data sets (Ramasamy et al., 2014). We found that rs7232 could not regulate the expression of genes in MS4A cluster in whole blood. Besides, rs7232 could not regulate the gene expression of MS4A6A or TREM2 in brain regions after Bonferroni correction. The association between the expressions of MS4A6A and TREM2 were also investigated. The expressions of MS4A6A and TREM2 are highly correlated in the whole brain ($p < 2 \times 10^{-16}$, Fig 5) and in all the 10 brain regions (Supplementary Fig. S3).

4. Discussion

We present a GWAS of CSF sTREM2 levels in the ADNI cohort and demonstrate that rs7232 in MS4A6A gene could influence CSF sTREM2 levels. The minor allele (A) of rs7232 in MS4A6A was associated with higher CSF sTREM2 levels in a dose-dependent fashion, especially in nondemented individuals. And the association was also observed in our replication cohort. Furthermore, the expressions of MS4A6A and TREM2 are highly correlated.

The role of TREM2 has been studied in the context of AD since the rare variant p.R47H in TREM2 was first discovered in 2013 (Guerreiro et al., 2013; Jonsson et al., 2013). Several AD-related TREM2 variants were found to affect the efficiency of TREM2 signaling, suggesting that altered TREM2 function participates in the development of AD (Ulrich et al., 2017). MS4A6A has also been demonstrated to be associated with AD risk in previous studies. Our group has reported that a common variant rs610932 in MS4A6A is strongly associated with decreased risk of AD (Tan et al., 2013). Rare variants in MS4A6A have also been identified to be associated with AD (Vardarajan et al., 2015). But the association between rare variants in MS4A6A and AD is




Fig. 2. CSF sTREM2 levels in different diagnostic groups and genotypes. The minor allele (A) of rs7232 showed significant association with higher CSF sTREM2 levels in a dose-dependent fashion in all diagnostic groups except the AD group. Abbreviations: AD, Alzheimer's disease; CSF, cerebrospinal fluid; sTREM2, soluble TREM2 protein; HC, healthy control; MCI, mild cognitive impairment.




Fig. 3. CSF sTREM2 levels in a replication cohort. Increased dose of the minor allele of rs7232 was significantly associated with increased CSF sTREM2 levels in an independent Chinese Han cohort of 377 participants ($p = 0.0106$). Abbreviations: CSF, cerebrospinal fluid; sTREM2, soluble TREM2 protein.




Fig. 4. Forest plot of the meta-analysis of the association between rs7232 and CSF sTREM2 levels. The meta-analysis showed that rs7232 was strongly associated with CSF sTREM2 levels ($p_{\text{meta}} = 1.59 \times 10^{-11}$). Abbreviations: ADNI, Alzheimer's Disease Neuroimaging Initiative; CABLE, Chinese Alzheimer's Biomarker and Lifestyle; CSF, cerebrospinal fluid; sTREM2, soluble TREM2 protein.

not clear as it has been reported that some rare deleterious variants in *MS4A* cluster were more frequent in controls than in patients with AD (Ghani et al., 2016). The expression of *MS4A6A* is upregulated in AD brains and associated with clinical dementia rating and Braak tangle score (Karch et al., 2012). But the underlying mechanism of *MS4A6A* involved in AD is still unknown. It was found in the present study that rs7232 which is an AD risk variant in *MS4A6A* could influence CSF sTREM2 levels, suggesting that *MS4A6A* may influence AD risk through the modification of sTREM2 levels. Similar results have been reported recently that *MS4A* gene cluster might be a regulator of sTREM2 (Deming et al., 2018). The SNP they identified in association with sTREM2 (rs1582763) was located between *MS4A4A* and *MS4A6E*. And the SNP was also identified in our study with p value of 1.24×10^{-12} . However, the association between rs1582763 and sTREM2 was not significant after controlling for rs7232. The participants in their study included much more AD cases than normal controls. But in our study, we have found that rs7232 was associated with sTREM2 levels especially in HC subjects and patients with MCI. This might be the reason for the different SNPs identified in their study. Which SNP is the key regulator of CSF sTREM2 needed further study.

The AD risk variant p.H157Y in *TREM2* gene could enhance TREM2 shedding, which increases the generation of sTREM2 (Schlepckow et al., 2017; Thornton et al., 2017). Levels of CSF sTREM2 have been reported to change following A β deposition. And CSF sTREM2 levels are correlated with CSF tau levels (Alosco et al., 2018; Suarez-Calvet et al., 2016a, b). But the potential role and functions of sTREM2 in AD pathology remain unclear. CSF sTREM2

could be a cause or a consequence of AD progression. It has been suggested that sTREM2 may have dual roles of promoting the production of inflammatory cytokines and enhancing microglial cell viability at the same time (Zhong et al., 2017). The result of our study that minor allele of rs7232 was associated with increased CSF sTREM2 levels and decreased AD risk is in favor of a protective role of sTREM2, although the mechanisms of sTREM2 involved in AD still need further study.

Subgroup analyses in the present study demonstrated that the SNPs in *MS4A6A* identified from GWAS mainly influence CSF sTREM2 levels in nondemented individuals including cognitively normal subjects and individuals with MCI. This is consistent with previous findings that sTREM2 was associated with the early stage of AD. In dominantly inherited patients with AD, CSF sTREM2 levels increased five years before the expected symptom onset (Suarez-Calvet et al., 2016a). Besides, sTREM2 could reflect the change of the microglial activation status, which occurs in the early stage of AD (Suarez-Calvet et al., 2016b). Besides, they have found that the CSF sTREM2 levels were higher in patients with MCI than those in normal controls and patients with AD. However, the change of CSF sTREM2 levels in AD is controversial. Although the sTREM2 levels were found to be increased in patients with AD in several studies (Piccio et al., 2016; Suarez-Calvet et al., 2016a, b), we and other groups found no significant difference in sTREM2 levels between different diagnostic groups (Deming et al., 2018; Henjum et al., 2016). Studies with larger sample size might address the question how sTREM2 levels changed during AD continuum and whether the SNPs in *MS4A6A* influence sTREM2 levels mainly in the early stage of AD. Previous gene coexpression network analysis has suggested that *TREM2* is a hub gene within an immune-gene-enriched module that contains *MS4A6D*, which is also in *MS4A* gene cluster (Matarin et al., 2015). Besides, the expression of caspase-4, which is an important part of the innate immune response, was strongly correlated with TREM2, *MS4A6A*, and the TREM2 adaptor protein TYROBP (Kajiwarra et al., 2016). These results suggested that TREM2 and *MS4A6A* expressions might play an important role in the immune response to AD pathology. Although the exact role of *MS4A6A* in AD is still unclear, it may have similar effects with *TREM2*, which participates in the regulation of microglia function (Jiang et al., 2016b). In our study, we also found that the expressions of *MS4A6A* and *TREM2* are highly correlated in the brain. sTREM2 was generated by the shedding of TREM. Both *MS4A6A* and TREM2 are expressed mainly on microglia in the brain (Darmanis et al., 2015). Thus, we think that *MS4A6A* may also play a role in the cleavage of TREM2. The increased expression of *MS4A6A* may enhance the cleavage of TREM2 and then increase CSF sTREM2 levels. And the




Fig. 5. Correlation between expression levels of *MS4A6A* and *TREM2*. The expressions of *MS4A6A* and *TREM2* are highly correlated in the whole brain ($p < 2 \times 10^{-16}$). Abbreviations: *MS4A6A*, membrane spanning 4-domains A6A.

changes in *TREM2* expression and CSF sTREM2 levels both contribute to the AD pathology.

There are some potential limitations in this study. First, the sample size in replication cohort is limited. The MAF of rs7223 is 0.32 in ADNI and 0.06 in CABLE study. Only 44 samples carried a minor allele A of rs7232 and no one carried homozygous A of rs7232 in the whole 377 samples from CABLE. This might be the reason for the discrepancy of *p* values between discovery and replication analyses. Power analysis showed that the estimated sample size is 4006 to achieve similar significant association in CABLE on 80% power. So larger sample size may better demonstrate the association between *MS4A6A* and CSF sTREM2 in Chinese because of the low MAF of rs7232 in Han population. Besides, larger cohorts for stratified analyses for each diagnostic group are needed to investigate the change in CSF sTREM2 during AD progression. Second, combined joint analysis of ADNI samples and our samples cannot be conducted because of the different ELISA kits used for the measurement of CSF sTREM2. Further studies are needed for the understanding of mechanisms whereby *MS4A6A* influences CSF sTREM2 levels.

In summary, we demonstrated that rs7232, an AD risk variant in *MS4A6A*, is associated with CSF sTREM2 levels especially in non-demented individuals. The expression of *MS4A6A* is highly correlated with the expression of *TREM2* in the brain. Our findings suggest that *MS4A6A* gene may participate in the regulation of sTREM2.

Disclosure

The authors have no conflicts of interest to disclose.

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (91849126), the National Key R&D Program of China (2018YFC1314700), Shanghai Municipal Science and Technology Major Project (No.2018SHZDZX01) and Zhangjiang Lab, Tianqiao and Chrissy Chen Institute, and the State Key Laboratory of Neurobiology and Frontiers Center for Brain Science of Ministry of Education, Fudan University. Data used in preparation of this article were obtained from the ADNI database (<http://adni.loni.ucla.edu/>). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc; Cogstate; Eisai Inc; Elan Pharmaceuticals, Inc; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc; Fujirebio; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co, Inc; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the

National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu).

The authors also thank the International Genomics of Alzheimer's Project (IGAP) for providing summary results data for these analyses. The investigators within IGAP contributed to the design and implementation of IGAP and/or provided data but did not participate in analysis or writing of this report. IGAP was made possible by the generous participation of the control subjects, the patients, and their families. The iSelect chips was funded by the French National Foundation on Alzheimer's disease and related disorders. EADI was supported by the Labex DISTALZ grant, Inserm, Institut Pasteur de Lille, Université de Lille 2, and the Lille University Hospital. GERAD was supported by the Medical Research Council (Grant number 503480), Alzheimer's Research UK (Grant number 503176), the Wellcome Trust (Grant number 082604/2/07/Z), and German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) grant number 01GI0102, 01GI0711, 01GI0420. CHARGE was partly supported by the NIH/NIA grant R01 AG033193 and the NIA AG081220 and AGES contract N01-AG-12100, the NHLBI grant R01 HL105756, the Icelandic Heart Association, and the Erasmus Medical Center and Erasmus University. ADGC was supported by the NIH/NIA grants: U01 AG032984, U24 AG021886, U01 AG016976, and the Alzheimer's Association grant ADGC-10-196728.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.neurobiolaging.2019.05.008>.

References

- Alonso, M.L., Tripodis, Y., Fritts, N.G., Heslegrave, A., Baugh, C.M., Conneely, S., Mariani, M., Martin, B.M., Frank, S., Mez, J., Stein, T.D., Cantu, R.C., McKee, A.C., Shaw, L.M., Trojanowski, J.Q., Blennow, K., Zetterberg, H., Stern, R.A., 2018. Cerebrospinal fluid tau, Abeta, and sTREM2 in Former National Football League players: modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration. *Alzheimers Dement.* 14, 1159–1170.
- Bajramovic, J.J., 2011. Regulation of innate immune responses in the central nervous system. *CNS Neurol. Disord. Drug Targets* 10, 4–24.
- Browning, B.L., Browning, S.R., 2007. Efficient multilocus association testing for whole genome association studies using localized haplotype clustering. *Genet. Epidemiol.* 31, 365–375.
- Darmanis, S., Sloan, S.A., Zhang, Y., Enge, M., Caneda, C., Shuer, L.M., Hayden Gephart, M.G., Barres, B.A., Quake, S.R., 2015. A survey of human brain transcriptome diversity at the single cell level. *Proc. Natl. Acad. Sci. U S A* 112, 7285–7290.
- Deming, Y., Filippello, F., Cignarella, F., Hsu, S., Mikesell, R., Li, Z., Del-Aguila, J.L., Dube, U., Farias, F.G., Bradley, J., Cantoni, C., Benitez, B., Budde, J., Ibanez, L., Fernandez, M.V., Blennow, K., Nelldard, B., Zetterberg, H., Heslegrave, A., Johansson, P.M., Svensson, J., Lleo, A., Alcolea, D., Clarimon, J., Rami, L., Molinuevo, J.L., Suarez-Calvet, M., Morenas-Rodriguez, E., Kleinberger, G., Ewers, M., Brett, T.J., Haass, C., Harari, O., Karch, C.M., Piccio, L., Cruchaga, C., 2018. The *MS4A* Gene Cluster Is a Key Regulator of Soluble *TREM2* and Alzheimer Disease Risk. *bioRxiv*, 352179. <https://www.biorxiv.org/content/10.1101/352179v1>.
- Frank, S., Burbach, G.J., Bonin, M., Walter, M., Streit, W., Bechmann, I., Deller, T., 2008. *TREM2* is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. *Glia* 56, 1438–1447.
- Gao, L., Jiang, T., Yao, X., Yu, L., Yang, X., Li, Y., 2017. *TREM2* and the progression of Alzheimer's disease. *Curr. Neurovasc. Res.* 14, 177–183.
- Ghani, M., Sato, C., Kakhiki, E.G., Gibbs, J.R., Traynor, B., St George-Hyslop, P., Rogava, E., 2016. Mutation analysis of the *MS4A* and *TREM* gene clusters in a case-control Alzheimer's disease data set. *Neurobiol. Aging* 42, e7–e13.
- Gispert, J.D., Suarez-Calvet, M., Monte, G.C., Tsucholka, A., Falcon, C., Rojas, S., Rami, L., Sanchez-Valle, R., Llado, A., Kleinberger, G., Haass, C., Molinuevo, J.L., 2016. Cerebrospinal fluid *sTREM2* levels are associated with gray matter volume

- increases and reduced diffusivity in early Alzheimer's disease. *Alzheimers Dement* 12, 1259–1272.
- Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J.S., Younkin, S., Hazrati, L., Collinge, J., Pocock, J., Lashley, T., Williams, J., Lambert, J.C., Amouyel, P., Goate, A., Rademakers, R., Morgan, K., Powell, J., St George-Hyslop, P., Singleton, A., Hardy, J., Alzheimer Genetic Analysis, G., 2013. TREM2 variants in Alzheimer's disease. *N. Engl. J. Med.* 368, 117–127.
- Hamelin, L., Lagarde, J., Dorothee, G., Leroy, C., Labit, M., Comley, R.A., de Souza, L.C., Corne, H., Dauphinot, L., Bertoux, M., Dubois, B., Gervais, P., Colliot, O., Potier, M.C., Bottlaender, M., Sarazin, M., Clinical, I.T., 2016. Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging. *Brain* 139 (Pt 4), 1252–1264.
- Henjum, K., Almdahl, I.S., Arskog, V., Minthon, L., Hansson, O., Fladby, T., Nilsson, L.N., 2016. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. *Alzheimers Res. Ther.* 8, 17.
- Heslegrave, A., Heywood, W., Paterson, R., Magdalino, N., Svensson, J., Johansson, P., Ohrfelt, A., Blennow, K., Hardy, J., Schott, J., Mills, K., Zetterberg, H., 2016. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. *Mol. Neurodegener.* 11, 3.
- Hsieh, C.L., Koike, M., Spusta, S.C., Niemi, E.C., Yenari, M., Nakamura, M.C., Seaman, W.E., 2009. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. *J. Neurochem.* 109, 1144–1156.
- Jiang, T., Tan, L., Chen, Q., Tan, M.S., Zhou, J.S., Zhu, X.C., Lu, H., Wang, H.F., Zhang, Y.D., Yu, J.T., 2016a. A rare coding variant in TREM2 increases risk for Alzheimer's disease in Han Chinese. *Neurobiol. Aging* 42, 217 e1–e3.
- Jiang, T., Zhang, Y.D., Chen, Q., Gao, Q., Zhu, X.C., Zhou, J.S., Shi, J.Q., Lu, H., Tan, L., Yu, J.T., 2016b. TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice. *Neuropharmacology* 105, 196–206.
- Jonsson, T., Stefansson, H., Steinberg, S., Jonsson, P.V., Snaedal, J., Björnsson, S., Huttenlocher, J., Levey, A.I., Lah, J.J., Rujescu, D., Hampel, H., Giegling, I., Andreassen, O.A., Engedal, K., Ulstein, I., Djurovic, S., Ibrahim-Verbaas, C., Hofman, A., Ikram, M.A., van Duijn, C.M., Thorsteinsdottir, U., Kong, A., Stefansson, K., 2013. Variant of TREM2 associated with the risk of Alzheimer's disease. *N. Engl. J. Med.* 368, 107–116.
- Kajiwar, Y., McKenzie, A., Dorr, N., Gama Sosa, M.A., Elder, G., Schmeidler, J., Dickstein, D.L., Bozdogi, O., Zhang, B., Buxbaum, J.D., 2016. The human-specific CASP4 gene product contributes to Alzheimer-related synaptic and behavioural deficits. *Hum. Mol. Genet.* 25, 4315–4327.
- Karch, C.M., Jeng, A.T., Nowotny, P., Cady, J., Cruchaga, C., Goate, A.M., 2012. Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains. *PLoS One* 7, e50976.
- Kim, S., Swaminathan, S., Shen, L., Risacher, S.L., Nho, K., Foroud, T., Shaw, L.M., Trojanowski, J.Q., Potkin, S.G., Huentelman, M.J., Craig, D.W., DeChairo, B.M., Aisen, P.S., Petersen, R.C., Weiner, M.W., Saykin, A.J., Alzheimer's Disease Neuroimaging Initiative, 2011. Genome-wide association study of CSF biomarkers Aβ₄₂–t-tau, and p-tau181p in the ADNI cohort. *Neurology* 76, 69–79.
- Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez, C., DeStafano, A.L., Bis, J.C., Beecham, G.W., Grenier-Boley, B., Russo, G., Thorton-Wells, T.A., Jones, N., Smith, A.V., Chouraki, V., Thomas, C., Ikram, M.A., Zelenika, D., Vardarajan, B.N., Kamatani, Y., Lin, C.F., Gerrish, A., Schmidt, H., Kunkle, B., Dunstan, M.L., Ruiz, A., Bihoreau, M.T., Choi, S.H., Reitz, C., Pasquier, F., Cruchaga, C., Craig, D., Amin, N., Berr, C., Lopez, O.L., De Jager, P.L., Deramecourt, V., Johnston, J.A., Evans, D., Lovestone, S., Letenneur, L., Moron, F.J., Rubinsztein, D.C., Eiriksdottir, G., Sleegers, K., Goate, A.M., Fievet, N., Huentelman, M.W., Gill, M., Brown, K., Kamboh, M.I., Keller, L., Barberger-Gateau, P., McGuinness, B., Larson, E.B., Green, R., Myers, A.J., Dufouil, C., Todd, S., Wallon, D., Love, S., Rogaeva, E., Gallacher, J., St George-Hyslop, P., Clarimon, J., Lleo, A., Bayer, A., Tsuang, D.W., Yu, L., Tsalaki, M., Bossu, P., Spalletta, G., Proitsi, P., Collinge, J., Sorbi, S., Sanchez-Garcia, F., Fox, N.C., Hardy, J., Deniz Naranjo, M.C., Bosco, P., Clarke, R., Brayne, C., Galimberti, D., Mancuso, M., Matthews, F., European Alzheimer's Disease, I., Genetic, Environmental Risk in Alzheimer's, D., Alzheimer's Disease Genetic, C., Cohorts for, H., Aging Research in Genomic, E., Moebus, S., Mecocci, P., Del Zompo, M., Maier, W., Hampel, H., Pilotto, A., Bullido, M., Panza, F., Caffarra, P., Nacmias, B., Gilbert, J.R., Mayhaus, M., Lannefelt, L., Hakonarson, H., Pichler, S., Carrasquillo, M.M., Ingelsson, M., Beekly, D., Alvarez, V., Zou, F., Valladares, O., Younkin, S.G., Coto, E., Hamilton-Nelson, K.L., Gu, W., Razquin, C., Pastor, P., Mateo, I., Owen, M.J., Faber, K.M., Jonsson, P.V., Combarros, O., O'Donovan, M.C., Cantwell, L.B., Soininen, H., Blacker, D., Mead, S., Mosley Jr., T.H., Bennett, D.A., Harris, T.B., Fratiglioni, L., Holmes, C., de Bruijn, R.F., Passmore, P., Montine, T.J., Bettens, K., Rotter, J.I., Brice, A., Morgan, K., Foroud, T.M., Kukull, W.A., Hannequin, D., Powell, J.F., Nalls, M.A., Ritchie, K., Lunetta, K.L., Kauwe, J.S., Boerwinkle, E., Riemenschneider, M., Boada, M., Hiltunen, M., Martin, E.R., Schmidt, R., Rujescu, D., Wang, L.S., Dartigues, J.F., Mayeux, R., Tzourio, C., Hofman, A., Nothen, M.M., Graff, C., Psaty, B.M., Jones, L., Haines, J.L., Holmans, P.A., Lathrop, M., Pericak-Vance, M.A., Launer, L.J., Farrer, L.A., van Duijn, C.M., Van Broeckhoven, C., Moskvina, V., Seshadri, S., Williams, J., Schellenberg, G.D., Amouyel, P., 2013. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat. Genet.* 45, 1452–1458.
- Matarin, M., Salih, D.A., Yasvoina, M., Cummings, D.M., Guelfi, S., Liu, W., Nahaboo Solim, M.A., Moens, T.G., Paublete, R.M., Ali, S.S., Perona, M., Desai, R., Smith, K.J., Latcham, J., Fulleylove, M., Richardson, J.C., Hardy, J., Edwards, F.A., 2015. A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. *Cell Rep* 10, 633–644.
- Neumann, H., Daly, M.J., 2013. Variant TREM2 as risk factor for Alzheimer's disease. *N. Engl. J. Med.* 368, 182–184.
- Piccio, L., Buonsanti, C., Cella, M., Tassi, I., Schmidt, R.E., Fenoglio, C., Rinker 2nd, J., Naismith, R.T., Panina-Bordignon, P., Passini, N., Galimberti, D., Scarpini, E., Colonna, M., Cross, A.H., 2008. Identification of soluble TREM2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. *Brain* 131 (Pt 11), 3081–3091.
- Piccio, L., Deming, Y., Del-Aguila, J.L., Ghezzi, L., Holtzman, D.M., Fagan, A.M., Fenoglio, C., Galimberti, D., Borroni, B., Cruchaga, C., 2016. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. *Acta Neuropathol.* 131, 925–933.
- Price, A.L., Patterson, N.J., Plenge, R.M., Weinblatt, M.E., Shadick, N.A., Reich, D., 2006. Principal components analysis corrects for stratification in genome-wide association studies. *Nat. Genet.* 38, 904–909.
- Ramasamy, A., Trabzuni, D., Guelfi, S., Varghese, V., Smith, C., Walker, R., De, T., UK Brain Expression Consortium, North American Brain Expression Consortium, Coin, L., de Silva, R., Cookson, M.R., Singleton, A.B., Hardy, J., Ryten, M., Weale, M.E., 2014. Genetic variability in the regulation of gene expression in ten regions of the human brain. *Nat. Neurosci.* 17, 1418–1428.
- Risch, N., Merikangas, K., 1996. The future of genetic studies of complex human diseases. *Science* 273, 1516–1517.
- Schleppack, K., Kleinberger, G., Fukumori, A., Feederle, R., Lichtenthaler, S.F., Steiner, H., Haass, C., 2017. An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function. *EMBO Mol. Med.* 9, 1356–1365.
- Suarez-Calvet, M., Araque Caballero, M.A., Kleinberger, G., Bateman, R.J., Fagan, A.M., Morris, J.C., Levin, J., Danek, A., Ewers, M., Haass, C., Dominantly Inherited Alzheimer Network, 2016. Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. *Sci. Transl. Med.* 8, 369ra178.
- Suarez-Calvet, M., Kleinberger, G., Araque Caballero, M.A., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleo, A., Blesa, R., Gispert, J.D., Sanchez-Valle, R., Antonell, A., Rami, L., Molinuevo, J.L., Brosseron, F., Traschütz, A., Heneka, M.T., Struyfs, H., Engelborghs, S., Sleegers, K., Van Broeckhoven, C., Zetterberg, H., Nelgard, B., Blennow, K., Crispin, A., Ewers, M., Haass, C., 2016. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. *EMBO Mol. Med.* 8, 466–476.
- Tan, L., Yu, J.T., Zhang, W., Wu, Z.C., Zhang, Q., Liu, Q.Y., Wang, W., Wang, H.F., Ma, X.Y., Cui, W.Z., 2013. Association of GWAS-linked loci with late-onset Alzheimer's disease in a northern Han Chinese population. *Alzheimers Dement* 9, 546–553.
- Thornton, P., Sevalle, J., Deery, M.J., Fraser, G., Zhou, Y., Stahl, S., Franssen, E.H., Dodd, R.B., Qamar, S., Gomez Perez-Nieves, B., Nicol, L.S., Eketjall, S., Revell, J., Jones, C., Billinton, A., St George-Hyslop, P.H., Chessell, I., Crowther, D.C., 2017. TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer's disease-associated H157Y variant. *EMBO Mol. Med.* 9, 1366–1378.
- Ulrich, J.D., Ulland, T.K., Colonna, M., Holtzman, D.M., 2017. Elucidating the role of TREM2 in Alzheimer's disease. *Neuron* 94, 237–248.
- Vardarajan, B.N., Ghani, M., Kahn, A., Sheikh, S., Sato, C., Barral, S., Lee, J.H., Cheng, R., Reitz, C., Lantigua, R., Reyes-Dumeyer, D., Medrano, M., Jimenez-Velazquez, I.Z., Rogaeva, E., St George-Hyslop, P., Mayeux, R., 2015. Rare coding mutations identified by sequencing of Alzheimer disease genome-wide association studies loci. *Ann. Neurol.* 78, 487–498.
- Westra, H.J., Peters, M.J., Esko, T., Yaghootkar, H., Schurmann, C., Kettunen, J., Christiansen, M.W., Fairfax, B.P., Schramm, K., Powell, J.E., Zernakova, A., Zernakova, D.V., Veldink, J.H., Van den Berg, L.H., Karjalainen, J., Withoff, S., Uitterlinden, A.G., Hofman, A., Rivadeneira, F., Hoern, P.A.C., Reinmaa, E., Fischer, K., Nelis, M., Milani, L., Melzer, D., Ferrucci, L., Singleton, A.B., Hernandez, D.G., Nalls, M.A., Homuth, G., Nauck, M., Radke, D., Volker, U., Perola, M., Salomaa, V., Brody, J., Suchy-Dicey, A., Gharib, S.A., Enquobahrie, D.A., Lumley, T., Montgomery, G.W., Makino, S., Prokisch, H., Herder, C., Roden, M., Grallert, H., Meitinger, T., Strauch, K., Li, Y., Jansen, R.C., Visscher, P.M., Knight, J.C., Psaty, B.M., Ripatti, S., Teumer, A., Frayling, T.M., Metspalu, A., van Meurs, J.B.J., Franke, L., 2013. Systematic identification of trans eQTLs as putative drivers of known disease associations. *Nat. Genet.* 45, 1238–1243.
- Zhong, L., Chen, X.F., Wang, T., Wang, Z., Liao, C., Wang, Z., Huang, R., Wang, D., Li, X., Wu, L., Jia, L., Zheng, H., Painter, M., Atagi, Y., Liu, C.C., Zhang, Y.W., Fryer, J.D., Xu, H., Bu, G., 2017. Soluble TREM2 induces inflammatory responses and enhances microglial survival. *J. Exp. Med.* 214, 597–607.